Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease)

Author(s): Zlatko Fras* and Dimitri P. Mikhailidis

Volume 19, Issue 5, 2021

Published on: 27 July, 2020

Page: [451 - 468] Pages: 18

DOI: 10.2174/1570161118999200727224946

Price: $65

Abstract

IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) was a randomized clinical trial (including 18,144 patients) that evaluated the efficacy of the combination of ezetimibe with simvastatin vs. simvastatin monotherapy in patients with acute coronary syndrome (ACS) and moderately increased low-density lipoprotein cholesterol (LDL-C) levels (of up to 2.6-3.2 mmol/L; 100-120 mg/dL). After 7 years of follow-up, combination therapy resulted in an additional LDL-C decrease [to 1.8 mmol/L, or 70 mg/dL, within the simvastatin (40 mg/day) monotherapy arm and to 1.4 mmol/L, or 53 mg/dL for simvastatin (40 mg/day) + ezetimibe (10 mg/day)] and showed an incremental clinical benefit [composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization (≥30 days after randomization), or nonfatal stroke; hazard ratio (HR) of 0.936, and 95% CI 0.887-0.996, p=0.016]. Therefore, for very high cardiovascular risk patients “even lower is even better” regarding LDL-C, independently of the LDL-C reducing strategy. These findings confirm ezetimibe as an option to treat very-high-risk patients who cannot achieve LDL-C targets with statin monotherapy. Additional analyses of the IMPROVE-IT (both prespecified and post-hoc) include specific very-high-risk subgroups of patients (those with previous acute events and/or coronary revascularization, older than 75 years, as well as patients with diabetes mellitus, chronic kidney disease or non-alcoholic fatty liver disease). The data from IMPROVE-IT also provide reassurance regarding longer-term safety and efficacy of the intensification of lipid-lowering therapy in very-high-risk patients resulting in very low LDL-C levels. We comment on the results of several (sub) analyses of IMPROVE-IT.

Keywords: Acute coronary syndrome, secondary prevention, low-density lipoprotein cholesterol-lowering, ezetimibe, simvastatin, combination therapy, IMPROVE-IT Trial.

« Previous Next »
[1]
WHO The top 10 causes of death 2018.www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
[2]
Timmis A, Townsend N, Gale CP, et al. European Society of Cardiology. European Society of Cardiology: Cardiovascular Disease Statistics 2019. Eur Heart J 2020; 41(1): 12-85.
[http://dx.doi.org/10.1093/eurheartj/ehz859] [PMID: 31820000]
[3]
Stone NJ, Robinson JG, Lichtenstein AH, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63(25 Pt B): 2889-934.
[http://dx.doi.org/10.1016/j.jacc.2013.11.002] [PMID: 24239923]
[4]
Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med 2016; 4(13): 256.
[http://dx.doi.org/10.21037/atm.2016.06.33] [PMID: 27500157]
[5]
Hess CN, Clare RM, Neely ML, et al. Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J 2017; 187: 194-203.
[http://dx.doi.org/10.1016/j.ahj.2017.01.016] [PMID: 28454804]
[6]
Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36(19): 1163-70.
[http://dx.doi.org/10.1093/eurheartj/ehu505] [PMID: 25586123]
[7]
Motivala AA, Tamhane U, Ramanath VS, et al. A prior myocardial infarction: how does it affect management and outcomes in recurrent acute coronary syndromes? Clin Cardiol 2008; 31(12): 590-6.
[http://dx.doi.org/10.1002/clc.20356] [PMID: 19072882]
[8]
Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 1979; 90(1): 85-91.
[http://dx.doi.org/10.7326/0003-4819-90-1-85] [PMID: 217290]
[9]
Keys A, Menotti A, Aravanis C, et al. The seven countries study: 2,289 deaths in 15 years. Prev Med 1984; 13(2): 141-54.
[http://dx.doi.org/10.1016/0091-7435(84)90047-1] [PMID: 6739443]
[10]
Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22.
[http://dx.doi.org/10.1016/S0140-6736(02)09327-3] [PMID: 12114036]
[11]
Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333(20): 1301-7.
[http://dx.doi.org/10.1056/NEJM199511163332001] [PMID: 7566020]
[12]
Campbell AW. Cardiovascular disease and statin drugs. Altern Ther Health Med 2014; 20(5): 8-9.
[PMID: 25141364]
[13]
Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-78.
[http://dx.doi.org/10.1016/S0140-6736(05)67394-1] [PMID: 16214597]
[14]
Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-81.
[http://dx.doi.org/10.1016/S0140-6736(10)61350-5] [PMID: 21067804]
[15]
Fulcher J, O’Connell R, Voysey M, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015; 385(9976): 1397-405.
[http://dx.doi.org/10.1016/S0140-6736(14)61368-4] [PMID: 25579834]
[16]
Masana L, Girona J, Ibarretxe D, et al. Clinical and pathophysiological evidence supporting the safety of extremely low LDL levels-The zero-LDL hypothesis. J Clin Lipidol 2018; 12(2): 292-99.
[http://dx.doi.org/10.1016/j.jacl.2017.12.018] [PMID: 29398429]
[17]
Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007; 14(3): 99-108.
[http://dx.doi.org/10.5551/jat.14.99] [PMID: 17587760]
[18]
Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012; 8: 415-27.
[PMID: 22910633]
[19]
Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009; 265(5): 568-80.
[http://dx.doi.org/10.1111/j.1365-2796.2008.02062.x] [PMID: 19141093]
[20]
Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23(8): 2009-26.
[http://dx.doi.org/10.1185/030079907X210507] [PMID: 17659159]
[21]
Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23(9): 2183-92.
[http://dx.doi.org/10.1185/030079907X226267] [PMID: 17692154]
[22]
Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008; 24(9): 2467-76.
[http://dx.doi.org/10.1185/03007990802303772] [PMID: 18655751]
[23]
Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011; 27(6): 1191-210.
[http://dx.doi.org/10.1185/03007995.2011.571239] [PMID: 21473671]
[24]
Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223(2): 251-61.
[http://dx.doi.org/10.1016/j.atherosclerosis.2012.02.016] [PMID: 22410123]
[25]
Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis 2017; 8(1): 4-11.
[http://dx.doi.org/10.1177/2040622316672544] [PMID: 28203346]
[26]
Rossebø AB, Pedersen TR, Boman K, et al. SEAS Investigators Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359(13): 1343-56.
[http://dx.doi.org/10.1056/NEJMoa0804602] [PMID: 18765433]
[27]
Baigent C, Landray MJ, Reith C, et al. SHARP Investigators The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377(9784): 2181-92.
[http://dx.doi.org/10.1016/S0140-6736(11)60739-3] [PMID: 21663949]
[28]
Tsujita K, Sugiyama S, Sumida H, et al. PRECISE–IVUS Investigators Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol 2015; 66(5): 495-507.
[http://dx.doi.org/10.1016/j.jacc.2015.05.065] [PMID: 26227186]
[29]
Cannon CP, Giugliano RP, Blazing MA, et al. IMPROVE-IT Investigators Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008; 156(5): 826-32.
[http://dx.doi.org/10.1016/j.ahj.2008.07.023] [PMID: 19061694]
[30]
Cannon CP, Blazing MA, Giugliano RP, et al. IMPROVE-IT Investigators Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372(25): 2387-97.
[http://dx.doi.org/10.1056/NEJMoa1410489] [PMID: 26039521]
[31]
Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Drugs 2018; 78(4): 453-62.
[http://dx.doi.org/10.1007/s40265-018-0870-1] [PMID: 29396832]
[32]
Sahebkar A, Simental-Mendía LE, Pirro M, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials. Sci Rep 2018; 8(1): 17887.
[http://dx.doi.org/10.1038/s41598-018-36204-7] [PMID: 30552391]
[33]
Bittner VA, Szarek M, Aylward PE, et al. ODYSSEY OUTCOMES Committees and Investigators Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol 2020; 75(2): 133-44.
[http://dx.doi.org/10.1016/j.jacc.2019.10.057] [PMID: 31948641]
[34]
Murphy SA, Cannon CP, Blazing MA, et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol 2016; 67(4): 353-61.
[http://dx.doi.org/10.1016/j.jacc.2015.10.077] [PMID: 26821621]
[35]
Blazing MA, Giugliano RP, de Lemos JA, et al. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J 2016; 182: 89-96.
[http://dx.doi.org/10.1016/j.ahj.2016.09.004] [PMID: 27914504]
[36]
Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2017; 136(25): 2440-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029095] [PMID: 28972004]
[37]
De Caterina R, Salvatore T, Marchioli R. Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. Atherosclerosis 2016; 248: 216-8.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.03.024] [PMID: 27035113]
[38]
Pandit AK, Kumar P, Kumar A, Chakravarty K, Misra S, Prasad K. High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand 2016; 134(1): 22-8.
[http://dx.doi.org/10.1111/ane.12540] [PMID: 26647879]
[39]
Judge C, Ruttledge S, Costello M, et al. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. J Stroke Cerebrovasc Dis 2019; 28(6): 1703-9.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2019.02.018] [PMID: 30878368]
[40]
Shin J, Chung JW, Jang HS, et al. Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials Eur J Prev Cardiol 2019. 2047487319830503
[http://dx.doi.org/10.1177/2047487319830503] [PMID: 30782002]
[41]
Ziff OJ, Banerjee G, Ambler G, Werring DJ. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2019; 90(1): 75-83.
[http://dx.doi.org/10.1136/jnnp-2018-318483] [PMID: 30150320]
[42]
Tan C, Liu X, Mo L, et al. Statin, cholesterol, and sICH after acute ischemic stroke: systematic review and meta-analysis. Neurol Sci 2019; 40(11): 2267-75.
[http://dx.doi.org/10.1007/s10072-019-03995-0] [PMID: 31267305]
[43]
Fras Z, Mikhailidis DP. Have we learnt all from IMPROVE-IT? Part II. Subanalyses on the effects of ezetimibe added to statin therapy on selected clinical and laboratory outcomes, cost effectiveness, guideline and clinical implications. Curr Vasc Pharmacol 2021; 19(5): 469-86.
[44]
Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129(9): 681-9.
[http://dx.doi.org/10.7326/0003-4819-129-9-199811010-00002] [PMID: 9841599]
[45]
Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134(10): 931-40.
[http://dx.doi.org/10.7326/0003-4819-134-10-200105150-00007] [PMID: 11352694]
[46]
Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360(9346): 1623-30.
[http://dx.doi.org/10.1016/S0140-6736(02)11600-X] [PMID: 12457784]
[47]
Cholesterol Treatment Trialists’ Collaboration Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019; 393(10170): 407-15.
[http://dx.doi.org/10.1016/S0140-6736(18)31942-1] [PMID: 30712900]
[48]
Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-81.
[http://dx.doi.org/10.1093/eurheartj/ehw106] [PMID: 27222591]
[49]
Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(24): 3210-27.
[http://dx.doi.org/10.1016/j.jacc.2018.11.004] [PMID: 30423394]
[50]
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73(24): 3168-209.
[http://dx.doi.org/10.1016/j.jacc.2018.11.002] [PMID: 30423391]
[51]
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 2017; 70(14): 1785-822.
[http://dx.doi.org/10.1016/j.jacc.2017.07.745] [PMID: 28886926]
[52]
Bach RG, Cannon CP, Giugliano RP, et al. Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2019; 4(9): 846-54.
[http://dx.doi.org/10.1001/jamacardio.2019.2306] [PMID: 31314050]
[53]
Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. J Am Coll Cardiol 2017; 69(8): 911-21.
[http://dx.doi.org/10.1016/j.jacc.2016.11.070] [PMID: 28231942]
[54]
Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK. Treating to New Targets Study Steering Committee and Investigators Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007; 147(1): 1-9.
[http://dx.doi.org/10.7326/0003-4819-147-1-200707030-00002] [PMID: 17606955]
[55]
Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115(6): 700-7.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.654756] [PMID: 17283260]
[56]
Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504.
[http://dx.doi.org/10.1056/NEJMoa040583] [PMID: 15007110]
[57]
Steg PG, Goldberg RJ, Gore JM, et al. GRACE Investigators Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 2002; 90(4): 358-63.
[http://dx.doi.org/10.1016/S0002-9149(02)02489-X] [PMID: 12161222]
[58]
Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291(15): 1864-70.
[http://dx.doi.org/10.1001/jama.291.15.1864] [PMID: 15100205]
[59]
Javed U, Deedwania PC, Bhatt DL, et al. Use of intensive lipidlowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospita participating in Get With The Guidelines (GWTG). Am Heart J 2011; 161(2): 418 -424.e1,3.
[http://dx.doi.org/10.1016/j.ahj.2010.12.014] [PMID: 21404720]
[60]
Kato ET, Cannon CP, Blazing MA, et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc 2017; 6(11)e006901
[http://dx.doi.org/10.1161/JAHA.117.006901] [PMID: 29151034]
[61]
Bohula EA, Bonaca MP, Braunwald E, et al. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction. Circulation 2016; 134(4): 304-13.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019861] [PMID: 27440003]
[62]
Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med 2012; 172(12): 909-19.
[http://dx.doi.org/10.1001/archinternmed.2012.2145] [PMID: 22732744]
[63]
Truong QA, Murphy SA, McCabe CH, Armani A, Cannon CP. TIMI Study Group Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes 2011; 4(3): 328-36.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.110.957720] [PMID: 21487089]
[64]
Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96(12): 4211-8.
[http://dx.doi.org/10.1161/01.CIR.96.12.4211] [PMID: 9416884]
[65]
Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32(1): 140-6.
[http://dx.doi.org/10.1016/S0735-1097(98)00202-2] [PMID: 9669262]
[66]
Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health (Larchmt) 2005; 14(1): 19-29.
[http://dx.doi.org/10.1089/jwh.2005.14.19] [PMID: 15692274]
[67]
Bennett S, Sager P, Lipka L, Melani L, Suresh R, Veltri E. Ezetimibe Study Group Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J Womens Health (Larchmt) 2004; 13(10): 1101-7.
[http://dx.doi.org/10.1089/jwh.2004.13.1101] [PMID: 15650343]
[68]
Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59(6): 572-82.
[http://dx.doi.org/10.1016/j.jacc.2011.09.067] [PMID: 22300691]
[69]
Stanifer JW, Charytan DM, White J, et al. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol 2017; 28(10): 3034-43.
[http://dx.doi.org/10.1681/ASN.2016090957] [PMID: 28507057]
[70]
Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604-12.
[http://dx.doi.org/10.7326/0003-4819-150-9-200905050-00006] [PMID: 19414839]
[71]
Kidney Disease Improving Global Outcomes Working Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3(1): 1-150.
[72]
Shepherd J, Kastelein JJ, Bittner V, et al. TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008; 51(15): 1448-54.
[http://dx.doi.org/10.1016/j.jacc.2007.11.072] [PMID: 18402899]
[73]
Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol 2007; 18(10): 2766-72.
[http://dx.doi.org/10.1681/ASN.2007020256] [PMID: 17804673]
[74]
Tokmakova MP, Skali H, Kenchaiah S, et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004; 110(24): 3667-73.
[http://dx.doi.org/10.1161/01.CIR.0000149806.01354.BF] [PMID: 15569840]
[75]
Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85(6): 1303-9.
[http://dx.doi.org/10.1038/ki.2014.31] [PMID: 24552851]
[76]
Katsiki N, Mikhailidis DP, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother 2019; 20(16): 2007-17.
[http://dx.doi.org/10.1080/14656566.2019.1649394] [PMID: 31344332]
[77]
Lin YC, Lai TS, Wu HY, et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther 2020; 108(4): 833-43.
[http://dx.doi.org/10.1002/cpt.1859] [PMID: 32320058]
[78]
Giugliano RP, Cannon CP, Blazing MA, et al. IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137(15): 1571-82.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030950] [PMID: 29263150]
[79]
Tsunoda T, Nozue T, Yamada M, Mizuguchi I, Sasaki M, Michishita I. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res Clin Pract 2013; 100(1): 46-52.
[http://dx.doi.org/10.1016/j.diabres.2012.12.026] [PMID: 23369229]
[80]
Guyton JR, Goldberg RB, Mazzone T, et al. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol 2008; 2(1): 19-24.
[http://dx.doi.org/10.1016/j.jacl.2007.12.004] [PMID: 21291711]
[81]
Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L, Zidan J. Ezetimibe’s effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 2008; 65(5): 637-45.
[http://dx.doi.org/10.1111/j.1365-2125.2007.03080.x] [PMID: 18241285]
[82]
Muñoz-Pacheco P, Ortega-Hernández A, Miana M, Cachofeiro V, Fernández-Cruz A, Gómez-Garre D. Ezetimibe inhibits PMA-induced monocyte/macrophage differentiation by altering microRNA expression: a novel anti-atherosclerotic mechanism. Pharmacol Res 2012; 66(6): 536-43.
[http://dx.doi.org/10.1016/j.phrs.2012.09.005] [PMID: 22989505]
[83]
Sternberg Z, Chichelli T, Sternberg D, et al. Quantitative and qualitative pleiotropic differences between Simvastatin single and Vytorin combination therapy in hypercholesterolemic subjects. Atherosclerosis 2013; 231(2): 411-20.
[http://dx.doi.org/10.1016/j.atherosclerosis.2013.09.031] [PMID: 24267260]
[84]
Qin L, Yang YB, Yang YX, et al. Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway. J Pharmacol Sci 2014; 125(3): 283-91.
[http://dx.doi.org/10.1254/jphs.13239FP] [PMID: 25048018]
[85]
Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464(7293): 1357-61.
[http://dx.doi.org/10.1038/nature08938] [PMID: 20428172]
[86]
Kataoka Y, Puri R, Hammadah M, et al. Cholesterol crystals associate with coronary plaque vulnerability in vivo. J Am Coll Cardiol 2015; 65(6): 630-2.
[http://dx.doi.org/10.1016/j.jacc.2014.11.039] [PMID: 25677323]
[87]
Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007; 29(11): 2419-32.
[http://dx.doi.org/10.1016/j.clinthera.2007.10.004] [PMID: 18158082]
[88]
Diffenderfer MR, Schaefer EJ. The composition and metabolism of large and small LDL. Curr Opin Lipidol 2014; 25(3): 221-6.
[http://dx.doi.org/10.1097/MOL.0000000000000067] [PMID: 24811298]
[89]
Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260(13): 1917-21.
[http://dx.doi.org/10.1001/jama.1988.03410130125037] [PMID: 3418853]
[90]
Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int J Obes 2008; 32(11): 1655-64.
[http://dx.doi.org/10.1038/ijo.2008.164] [PMID: 18779822]
[91]
Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5(3): 928-48.
[http://dx.doi.org/10.3390/nu5030928] [PMID: 23507795]
[92]
Berneis K, Jeanneret C, Muser J, Felix B, Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes. Metabolism 2005; 54(2): 227-34.
[http://dx.doi.org/10.1016/j.metabol.2004.08.017] [PMID: 15690318]
[93]
Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23(5): 1169-76.
[http://dx.doi.org/10.1185/030079907X188062] [PMID: 17519084]
[94]
Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008; 24(7): 1919-29.
[http://dx.doi.org/10.1185/03007990802177150] [PMID: 18513463]
[95]
Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017; 23(Suppl. 2): 1-87.
[http://dx.doi.org/10.4158/EP171764.APPGL] [PMID: 28437620]
[96]
Wilson PW, D’Agostino R Sr, Bhatt DL, et al. REACH Registry. An international model to predict recurrent cardiovascular disease. Am J Med 2012; 125(7): 695-703.e1.
[http://dx.doi.org/10.1016/j.amjmed.2012.01.014] [PMID: 22727237]
[97]
Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45(4): 846-54.
[http://dx.doi.org/10.1002/hep.21496] [PMID: 17393509]
[98]
Sterling RK, Lissen E, Clumeck N, et al. APRICOT Clinical Investigators Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43(6): 1317-25.
[http://dx.doi.org/10.1002/hep.21178] [PMID: 16729309]
[99]
Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57(4): 1357-65.
[http://dx.doi.org/10.1002/hep.26156] [PMID: 23175136]
[100]
Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191(2): 391-6.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.04.006] [PMID: 16682043]
[101]
Schillinger M, Exner M, Mlekusch W, et al. Serum albumin predicts cardiac adverse events in patients with advanced atherosclerosis - interrelation with traditional cardiovascular risk factors. Thromb Haemost 2004; 91(3): 610-8.
[http://dx.doi.org/10.1160/TH03-08-0504] [PMID: 14983239]
[102]
Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb Haemost 2010; 8(1): 148-56.
[http://dx.doi.org/10.1111/j.1538-7836.2009.03584.x] [PMID: 19691485]
[103]
Yoshihisa A, Sato Y, Yokokawa T, et al. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018; 5(2): 262-70.
[http://dx.doi.org/10.1002/ehf2.12222] [PMID: 28967709]
[104]
Simon TG, Corey KE, Cannon CP, et al. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018; 270: 245-52.
[http://dx.doi.org/10.1016/j.ijcard.2018.05.087] [PMID: 29903515]
[105]
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. Writing Committee 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016; 68(1): 92-125.
[http://dx.doi.org/10.1016/j.jacc.2016.03.519] [PMID: 27046161]
[106]
Tan M, MacEachern MP. Treating Dyslipidemias in the Primary Prevention of Atherosclerotic Cardiovascular Disease in Older Adults with Diabetes Mellitus. Clin Geriatr Med 2020; 36(3): 457-76.
[http://dx.doi.org/10.1016/j.cger.2020.04.006] [PMID: 32586475]
[107]
Athyros VG, Alexandrides TK, Bilianou H, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism 2017; 71: 17-32.
[http://dx.doi.org/10.1016/j.metabol.2017.02.014] [PMID: 28521870]

Rights & Permissions Print Cite
Article Metrics
50
1
© 2024 Bentham Science Publishers | Privacy Policy